Equities research analysts predict that Stryker Co. (NYSE:SYK) will announce $1.68 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Eleven analysts have issued estimates for Stryker’s earnings. The lowest EPS estimate is $1.66 and the highest is $1.70. Stryker reported earnings of $1.52 per share in the same quarter last year, which suggests a positive year over year growth rate of 10.5%. The business is expected to report its next earnings results on Thursday, October 25th.

On average, analysts expect that Stryker will report full-year earnings of $7.25 per share for the current year, with EPS estimates ranging from $7.23 to $7.27. For the next fiscal year, analysts anticipate that the business will post earnings of $7.97 per share, with EPS estimates ranging from $7.89 to $8.08. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Stryker.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, July 24th. The medical technology company reported $1.76 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.73 by $0.03. The firm had revenue of $3.32 billion for the quarter, compared to analyst estimates of $3.31 billion. Stryker had a return on equity of 26.93% and a net margin of 8.28%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.53 earnings per share.

A number of analysts have recently commented on the company. Zacks Investment Research lowered Stryker from a “buy” rating to a “hold” rating in a report on Friday, May 18th. ValuEngine lowered Stryker from a “buy” rating to a “hold” rating in a report on Tuesday, June 12th. Cantor Fitzgerald restated a “hold” rating and issued a $170.00 price target on shares of Stryker in a report on Wednesday, June 13th. Sanford C. Bernstein assumed coverage on Stryker in a report on Wednesday, June 27th. They issued a “market perform” rating and a $177.00 price target on the stock. Finally, BMO Capital Markets restated a “hold” rating and issued a $174.00 price target on shares of Stryker in a report on Thursday, July 12th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and fifteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $177.25.

SYK stock traded down $0.86 during midday trading on Tuesday, hitting $168.57. 38,194 shares of the company’s stock were exchanged, compared to its average volume of 928,539. The company has a current ratio of 1.83, a quick ratio of 1.15 and a debt-to-equity ratio of 0.63. The firm has a market cap of $63.37 billion, a PE ratio of 25.94, a P/E/G ratio of 2.38 and a beta of 0.59. Stryker has a one year low of $138.56 and a one year high of $179.84.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. River Wealth Advisors LLC increased its position in Stryker by 1.1% during the first quarter. River Wealth Advisors LLC now owns 29,300 shares of the medical technology company’s stock worth $4,715,000 after buying an additional 309 shares during the last quarter. CapWealth Advisors LLC increased its position in Stryker by 0.8% during the second quarter. CapWealth Advisors LLC now owns 40,753 shares of the medical technology company’s stock worth $6,882,000 after buying an additional 310 shares during the last quarter. Benedict Financial Advisors Inc. increased its position in Stryker by 7.2% during the second quarter. Benedict Financial Advisors Inc. now owns 4,681 shares of the medical technology company’s stock worth $790,000 after buying an additional 313 shares during the last quarter. Janney Montgomery Scott LLC increased its position in Stryker by 1.5% during the second quarter. Janney Montgomery Scott LLC now owns 21,307 shares of the medical technology company’s stock worth $3,598,000 after buying an additional 316 shares during the last quarter. Finally, Mogy Joel R Investment Counsel Inc. increased its position in Stryker by 0.4% during the first quarter. Mogy Joel R Investment Counsel Inc. now owns 86,568 shares of the medical technology company’s stock worth $13,931,000 after buying an additional 325 shares during the last quarter. Institutional investors and hedge funds own 75.08% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Recommended Story: Return on Investment (ROI) Defined, Explained

Get a free copy of the Zacks research report on Stryker (SYK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.